Heart failure with reduced ejection fraction (HFrEF) is a progressive and debilitating condition with significant morbidity and mortality. Despite advancements in heart failure management, many patients continue to experience worsening symptoms and poor outcomes, highlighting critical unmet needs. This course focuses on the continuum of HFrEF progression and explores the role of Vericiguat, an innovative therapy targeting the underlying pathophysiology. Participants will gain insights into the clinical benefits, mechanisms of action, and practical applications of Vericiguat in addressing these gaps, ultimately improving care for patients with HFrEF.
Course Content
Continuum in progression of HFrEF: Addressing unmet needs with Vericiguat